Clinical Trial: JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

U.S., April 26 -- ClinicalTrials.gov registry received information related to the study (NCT06386146) titled 'JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation' on April 23.

Brief Summary: This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.

Study Type: Interventional

Condition: Solid Tumors

Intervention: Drug: JAB-30355

Oral administration

Recruitment Status: Not Yet Recruiting

Published by HT Digital Content Services with permission from Health Daily Digest....